Oral surveillance and JAK inhibitor safety: the theory of relativity
Nat Rev Rheumatol. 2022. Epub ahead of print doi: 10.1038/s41584-022-00767-7
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Nat Rev Rheumatol. 2022. Epub ahead of print doi: 10.1038/s41584-022-00767-7
RMD Open. 2022;8(1):e002012 doi: 10.1136/rmdopen-2021-002012
Clin Rheumatol. 2022 Jan 1. Epub ahead of print doi: 10.1007/s10067-021-05908-z
Clin Rheumatol. 2022. Epub ahead of print doi: 10.1007/s10067-021-06003-z
Ann Rheum Dis. 2022 Jan 13. Epub ahead of print doi: 10.1136/annrheumdis-2021-221915
N Engl J Med 2022;386:316–26. doi: 10.1056/NEJMc2202778
Rheumatol Ther. 2021. Epub ahead of print. doi: 10.1007/s40744-021-00390-0
ACR Open Rheumatol. 2021. Epub ahead of print. doi: 10.1002/acr2.11380
J Clin Rheumatol. 2021;27(8):e482–e490
J Crohns Colitis. 2022 Jan 28;16(1):27-38 doi: 10.1093/ecco-jcc/jjab133
The authors highlighted a significantly greater clinical remission rate at Week 52 for vedolizumab SC versus placebo in patients with moderately to severely active CD. This study aimed to report results from VISIBLE 2 which evaluated a new SC vedolizumab formulation as maintenance treatment in adults with moderately to severely active CD.